Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A new radiopharmaceutical, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO) has shown considerable promise for single photon emission tomographic (SPECT) imaging of the brain. In animal biodistribution studies this complex demonstrates good brain uptake with prolonged retention of activity in brain. Further improvement of these properties, resulting in higher brain uptake with very slow washout and fixed regional distribution has been achieved following the isolation of the d,1-diastereoisomer of HM-PAO.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Nucl Med Commun

Title: Nuclear medicine communications

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN: 0143-3636

ISSN (Print): 0143-3636

Publication date (Electronic): Sep 1985

Volume: 6

Issue: 9

Article

DOI: 10.1097/00006231-198509000-00002

PubMed ID: 3877892

SO-VID: 62e6f6aa-6277-4876-ab30-86d64a5e4e57

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 3

See all cited by